Compare Hinge Health Inc. Class A Common Stock (HNGE) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs ArcelorMittal SA — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while ArcelorMittal SA trades at $62.47 (market cap $47.40B). The key difference: ArcelorMittal SA is far larger — about 5.6× Hinge Health Inc. Class A Common Stock's market cap, and ArcelorMittal SA pays a 0.96% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and ArcelorMittal SA for 36 Days on average.
| HNGE | MT | |
|---|---|---|
Market Cap | $8.47B | $47.40B |
Volume | 1,624,526 | 869,267 |
Sector | Health | Basic Materials |
52-Week High | $105.14 | $78.74 |
52-Week Low | $31.17 | $36.91 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $8.09B | $56.97B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
ArcelorMittal (MT) trades at $63.47, up 0.83% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent Ukraine plant impairments and missile strikes create operational headwinds, while analyst consensus remains bullish with a $74.33 price target representing 17% upside potential.
MT offers value with attractive valuation ratios (P/S 0.77, P/B 0.87) and strong cash flow generation, but faces significant geopolitical risks and declining revenue trends. The company's strategic shift toward regional operations and shareholder returns provides upside, though investors must weigh Ukraine-related impairments and steel demand volatility against the positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
